Notice of Proposed Sale · 144
Annexon, Inc.
ANNXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Annexon, Inc.
- Issuer CIK
- 0001528115
- SEC file number
- 001-39402
- Phone
- (650) 822-5500
- Person for whose account securities are to be sold
- WIGGANS THOMAS G
- Relationships to issuer
- Former Director
- Street
- 1400 SIERRA POINT PARKWAY
- Street (continued)
- BLDG C, SUITE 200
- City
- BRISBANE
- State / country code
- CA
- Postal code
- 94005
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,000 | 5,605.00 | 163,842,538 | 07/14/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/14/2026 | Stock Option Exercise | Issuer | 1,000 | N | 07/14/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 07/14/2026
- Signed
- /s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Thomas Wiggans
Company context
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Current securities
Recent company filings
- 10-Q filingAug 12, 2026
- Results of Operations and Financial Condition · Other EventsAug 12, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 10, 2026
- Other EventsAug 6, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other EventsJul 30, 2026